ABT · News · 20261105N
Product Launch and Transition
ABBOTT LABORATORIES · 2026-11-05 · Importance 31 · Surprise 42 · In source text
Abbott and Novo expanded their collaboration to launch Plosbrio® (semaglutide) in Singapore and other Asia Pacific countries. Plosbrio is a second brand of Ozempic® intended to broaden access to advanced type 2 diabetes care. The reported benefits include HbA1c reduction, weight loss, and reduced cardiovascular and kidney-event risk for adults with type 2 diabetes; the partnership draws on Novo’s GLP-1 expertise and Abbott’s regional healthcare footprint.
Key facts
- Abbott and Novo plan to launch Plosbrio® (semaglutide) across Singapore and other Asia Pacific countries. source
- Plosbrio® is a second brand of Ozempic®. source
- Plosbrio® offers benefits in HbA1c reduction, weight loss, and reduced risk of cardiovascular and kidney events for adults with type 2 diabetes. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Abbott and Novo plan to launch Plosbrio® (semaglutide) across Singapore and other Asia Pacific countries. |